Skip to main navigation
Company Logo
  • About
    • About Overview
    • Leadership
    • Careers
  • Product
    • RECELL® System
  • Clinical Development
    • Pipeline/Clinical Trials
    • Patient Outcomes
    • Proof Assets
  • News & Media
  • Investor Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Annual Reports & Proxy
    • Stock Information
    • Corporate Governance
    • FAQ
    • Email Alerts
    • Contact
  • Contact
  • Search
  • Overview
  • Press Releases
  • Events & Presentations
  • Financials
  • Annual Reports & Proxy
  • Stock Information
  • Corporate Governance
  • FAQ
  • Email Alerts
  • Contact
/press-releases/news-releases
global

Investors: Press Releases

AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance
January 7, 2025
Learn More
AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds
December 23, 2024
Learn More
AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market
December 19, 2024
Learn More
  • News Releases
  • Announcements
January 7, 2025
AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance
AVITA Medical, Inc. Logo with tag

Contact Investor Relations

Jessica Ekeberg
Director, Investor Relations
investor@avitamedical.com

Request Email Alerts
® 2025 AVITA Medical, Inc.
  • Terms of Use
  • Privacy Policy
  • CA Compliance
  • Social Media
  • CCPA
  • Compliance and Ethics
  • Important Safety Information

Social Media

  • Twitter (opens in new window)
  • Linkedin (opens in new window)